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Abstract
Theworking group “Analyses in Biological Materials” of the Permanent Senate Com-
mission for the Investigation of Health Hazards of Chemical Compounds in theWork
Area verified the presented biomonitoring method.
The method described hereinafter permits the selective determination of 3,5-di-tert-
butyl-4-hydroxybenzoic acid (BHT acid) as a metabolite of butylated hydroxytoluene
(BHT) in urine. After adding a 13C6-ring labelled internal standard (ISTD), the samples
are enzymatically hydrolysed to release the free BHT acid from glucuronidated com-
pounds. Using two-dimensional liquid chromatography the samples are concentrated
and separated from matrix components and analysed using tandem mass spectrome-
try. Calibration is done using calibration standards prepared in water and processed
in the same way as the samples to be analysed.
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1 Characteristics of the method
Matrix Urine
Analytical principle LC-MS/MS
Parameter and corresponding hazardous substance
Hazardous substance CAS No. Parameter CAS No.
Butylated hydroxytoluene (BHT) 128-37‑0 3,5-Di-tert-butyl-4-hydroxybenzoic acid (BHT acid) 1421-49‑4
Reliability data
3,5-Di-tert-butyl-4-hydroxybenzoic acid (BHT acid)
Standard deviation (rel.) sw  = 4.0%, 5.1%, 4.5% or 6.0%
Prognostic range u = 8.9%, 11.4%, 10.0% or 13.5%
Within-day precision:
at a spiked concentration of 0.1 µg, 1.0 µg, 10.0 µg or 100 µg BHT acid per litre
water and where n = 10 determinations
Standard deviation (rel.) sw  = 9.7%, 8.1%, 11.0% or 10.0%
Prognostic range u = 21.8%, 18.2%, 24.8% or 22.5%
Day-to-day precision:
at a spiked concentration of 0.1 µg, 1.0 µg, 10.0 µg or 100 µg BHT acid per litre
water and where n = 10 determinations
Recovery rate (rel.) r = 101%, 103%, 101% or 102%Accuracy:
at a spiked concentration of 0.1 µg, 1.0 µg, 10.0 µg or 100 µg BHT acid per litre
water and where n = 10 determinations
Detection limit: 0.06 µg BHT acid per litre water
Quantitation limit: 0.2 µg BHT acid per litre water
2 General information on BHT
Butylated hydroxytoluene (BHT) (2,6-di-tert-butyl-p-cresol, 3,5-di-tert-butyl-4-hydroxytoluene) was patented in
1947 and initially used as a stabiliser in the petroleum and adhesives industries. Due to its antioxidant proper-
ties, its application range was extended back in the 1950s to include the stabilisation of foodstuffs and cosmetics
(Witschi et al. 1989). Today it is one of the most prevalent synthetic antioxidants (Nieva-Echevarria et al. 2015), the
antioxidant properties of which are attributable to the radical scavenging, sterically hindered phenol group.
Accordingly, the range of applications in the food sector is wide: it is added as an antioxidant (E 321) in particular
to baking mixtures, nuts, packet soups, chewing gums as well as fats and oils. Regulation (EC) No. 1333/2008
(EU 2008) sets maximum contents for this additive in various foodstuffs. Other applications include the addition
in pharmaceuticals (ointments, gelatine capsules), cosmetics (shower gels, soaps), plastics and rubber products as
well as paints and varnishes.
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BHT is industrially produced by the reaction of p-cresol with 2‑methylpropene catalysed by sulphuric acid. The
global production volume in 2000 was approximately 62,000 t/a (OECD 2002).
BHT is a white solid consisting of colourless crystals and has a mild phenolic odour. Its melting point is 70 ℃ and
it is almost insoluble in water (0.76 mg/l). BHT is marketed under various trade names, including Vulkanox-BHT,
Ionol, Paranox 441, Impruvol or Antioxidant 4K.
At the workplace inhalation is the major route of exposure to BHT, but dermal absorption is also possible, although
after dermal application only 4% of the applied amount penetrates the skin, indicating that systemic bioavailability
is rather low (Henschler 1986).
Several metabolic pathways and numerous metabolites are known for BHT. Metabolism studies of BHT in rats, mice
and rabbits have shown that chemical reactions during metabolism can take place in three positions: on the ring,
on the methyl group as well as on the tert-butyl groups. The primary metabolic pathway in rodents and humans
leads to BHT acid by stepwise oxidation of the 4‑methyl group via BHT alcohol and BHT aldehyde (see Figure 1)
(Henschler 1986; Nieva-Echevarria et al. 2015). The few available data on the metabolism of BHT in humans show
that up to 5% of the resorbed BHT dose is excreted in urine as BHT acid, most of which is glucuronidated (Daniel












Fig. 1 Primary metabolic pathway of BHT to BHT acid (Henschler 1986)
Elimination takes place in two phases: in the α-phase, elimination is rapid and takes place predominantly via the
urine. In the β-phase, the elimination half-life is approximately 10 days as a result of an extensive enterohepatic
circulation of the metabolites or their accumulation in adipose tissue. In humans, BHT and its metabolites are
excreted primarily in the urine, while in rats they are also eliminated via the faeces (Greim 2007; Lanigan and
Yamarik 2002).
BHT was classified by the Commission as a Category 4 carcinogen. The MAK value was set at 10 mg BHT/m3 E
(DFG 2019; Hartwig 2012). Since absorption through the skin does not contribute significantly to the internal load,
BHT was not designated with an “H”. It has not been designated with “Sh” or “Sa” either. EFSA derived an ADI level
(Acceptable Daily Intake) of 0.25 mg/kg body weight per day (EFSA 2012). Reference or limit values in biological
material are not available. For further details on the toxicological evaluation of BHT, please refer to the respective
MAK value documentations of the Commission (Greim 2007; Hartwig 2012; Henschler 1986).
Due to the widespread use of BHT in many areas of life, a potential exposure of the general population can be
assumed. Table 1 shows data on the background exposure of the general population from several studies.
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Tab. 1 Data on the background exposure of the general population to BHT, specifying the BHT acid excretion in urine
BHT acid [µg/l]Country Number of samples
(> LOQ) Mean value (median) Range
Reference
Japan  24 (91.7%) 5.49 (3.86) < LOQ–24.4
India  36 (94.3%) 5.15 (2.24) < LOQ–24.0
China  53 (80.4%) 0.56 (0.26) < LOQ–4.98
Saudi Arabia   9 (100%) 1.46 (0.44) 0.11–5.63
U.S.  23 (95.7%) 7.44 (1.78) < LOQ–46.0
Wang and Kannan 2019
Germany  40 (82.5%) 1.28 (0.83) < LOQ–7.55 Leng and Gries 2017
Germany  10 (100%) 8.66 (3.75) 0.7–35.4 data obtained during external
method verification
Germany 329 (98%) 1.70 (1.06) < LOQ–18.1 Schmidtkunz et al. 2020
Germany  22 (91%) n. s. (0.91) < LOQ–12.7 Göen et al. 2006
LOQ: limit of quantitation; n. s.: not specified
3 General principles
The method described hereinafter permits the selective determination of 3,5-di-tert-butyl-4-hydroxybenzoic acid
(BHT acid) as a metabolite of butylated hydroxytoluene (BHT) in urine. After adding a 13C6-ring labelled inter-
nal standard (ISTD), the samples are enzymatically hydrolysed to release the free BHT acid from glucuronidated
compounds. Using two-dimensional liquid chromatography the samples are concentrated and separated from ma-
trix components and analysed using tandem mass spectrometry. Calibration is done using calibration standards
prepared in water and processed in the same way as the samples to be analysed.
4 Equipment, chemicals and solutions
4.1 Equipment
• UPLC-MS/MS system: Waters Acquity UPLC with 2D-LC option coupled with Waters Xevo-TQS tandem mass
spectrometer (Waters GmbH, Eschborn, Germany)
• LC column: Zorbax RRHD Eclipse Plus C8 1.8 μm, 2.1 mm × 100 mm (Agilent Technologies Deutschland GmbH,
Waldbronn, Germany, No. 959758-906)
• Pre-concentration column: XBridge BEH C8 Direct Connect HP 10 μm, 2.1 mm × 30 mm (Waters GmbH,
Eschborn, Germany, No. 186005233)
• Trap column, e.g. Oasis HLB Direct Connect HP 20 μm, 2.1 mm × 30 mm (Waters GmbH, Eschborn, Germany,
No. 186005231)
• Laboratory shaker (e.g. IKA Werke GmbH & Co. KG, Staufen, Germany)
• Analytical balance (e.g. Sartorius AG, Göttingen, Germany)
• Incubator (e.g. Memmert GmbH & Co. KG, Schwabach, Germany)
• Various volumetric flasks and beakers (e.g. BRAND GMBH + CO KG, Wertheim, Germany)
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• Microlitre pipettes, variably adjustable from 10 µl to 100 µl as well as from 100 µl to 1000 µl (e.g. Eppendorf
AG, Hamburg, Germany)
• Multipette (e.g. Eppendorf AG, Hamburg, Germany)
• 2 ml vials and crimp caps (e.g. Waters GmbH, Eschborn, Germany, No. 186000327C)
• pH meter (e.g. Mettler-Toledo GmbH, Gießen, Germany)
• Universal pH test paper, pH 0–11 (e.g. MACHEREY-NAGEL GmbH & Co. KG, Düren, Germany)
• Urine containers (e.g. Sarstedt AG & Co. KG, Nürnbrecht, Germany)
4.2 Chemicals
Unless otherwise specified, all chemicals must be at least p.a. grade.
• Acetonitrile, hypergrade for LC-MS (e.g. Merck KGaA, Darmstadt, Germany, No. 1.00029)
• Ultrapure water, CHROMASOLVTM (e.g. Honeywell Specialty Chemicals Seelze GmbH, Seelze, Germany,
No. 39253)
• β-Glucuronidase (e.g. Roche Diagnostics Deutschland GmbH, Mannheim, Germany, No. 03707598001)
• Glacial acetic acid, Suprapur® (e.g. Merck KGaA, Darmstadt, Germany, No. 1.00066)
• Formic acid (e.g. Merck KGaA, Darmstadt, Germany, No. 533002)
• Ammonium acetate (e.g. Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany, No. 73594)
• 3,5-Di-tert-butyl-4-hydroxybenzoic acid (BHT acid), 98% (e.g. Sigma-Aldrich Chemie GmbH, Taufkirchen,
Germany, No. 143472)
• 3,5-Di-tert-butyl-4-hydroxybenzoic acid-13C6 (ring substituted) (13C6-BHT acid), 97% (custom synthesis, Insti-
tut für Dünnschichttechnologie und Mikrosensorik e. V., Teltow, Germany)
4.3 Solutions
• Ammonium acetate buffer (1 mol/l)
Exactly 38.5 g ammonium acetate are weighed into a 400 ml beaker and dissolved in approximately 250 ml
ultrapure water. After the pH has been adjusted to 6.5 (pH meter) with glacial acetic acid, the solution is
quantitatively transferred to a 500 ml volumetric flask. The flask is then made up to the mark with ultrapure
water.
• Mobile phase for UPLC (mobile phase A)
1 ml formic acid is pipetted into a 1000 ml volumetric flask.The flask is then filled up to the mark with ultrapure
water and the solution well mixed.
• Mobile phase for UPLC (mobile phase B)
1 ml formic acid is pipetted into a 1000 ml volumetric flask. The flask is then filled up to the mark with ace-
tonitrile and the solution well mixed.
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The solutions are stable at 4 ℃ for at least six months.
4.4 Internal standard (ISTD)
• ISTD stock solution I (1000 mg/l)
10 mg of the 13C6-BHT acid are weighed exactly into a 10 ml volumetric flask and dissolved in acetonitrile. The
flask is then made up to the mark with acetonitrile.
• ISTD stock solution II (10 mg/l)
100 µl of the ISTD stock solution I are pipetted into a 10 ml volumetric flask. The flask is then made up to the
mark with acetonitrile.
• ISTD spiking solution (1 mg/l)
1 ml of the ISTD stock solution II is pipetted into a 10 ml volumetric flask. The flask is then made up to the
mark with acetonitrile.
The ISTD solutions are stable for at least three months when stored in the refrigerator at 4 ℃.
4.5 Calibration standards
• Stock solution (1000 mg/l)
10 mg BHT acid are weighed into a 10 ml volumetric flask and dissolved in acetonitrile. The flask is then made
up to the mark with acetonitrile.
• Spiking solution I (10 mg/l)
100 μl of the stock solution are pipetted into a 10 ml volumetric flask. The flask is then made up to the mark
with acetonitrile.
• Spiking solution II (1 mg/l)
1 ml of spiking solution I is pipetted into a 10 ml volumetric flask. The flask is then made up to the mark with
acetonitrile.
• Spiking solution III (100 µg/l)
100 μl of spiking solution I are pipetted into a 10 ml volumetric flask. The flask is then made up to the mark
with acetonitrile.
• Spiking solution IV (10 µg/l)
100 μl of spiking solution II are pipetted into a 10 ml volumetric flask. The flask is then made up to the mark
with acetonitrile.
• Spiking solution V (1 µg/l)
1 ml of spiking solution IV is pipetted into a 10 ml volumetric flask. The flask is then made up to the mark with
acetonitrile.
The stock solutions and spiking solutions can be stored at 4 ℃ for at least three months without analyte loss.
Calibration standards in the concentration range between 0.01 µg/l and 200 µg/l are prepared in ultrapure water
according to the pipetting scheme shown in Table 2. Ultrapure water is included as a blank value.
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Tab. 2 Pipetting scheme for the preparation of calibration standards used to determine BHT acid in urine
Volume of the spiking
solution






 1 – – 500   0
 2 V  5 495   0.01
 3 V 10 490   0.02
 4 V 25 475   0.05
 5 IV  5 495   0.1
 6 IV 10 490   0.2
 7 IV 25 475   0.5
 8 III  5 495   1.0
 9 III 10 490   2.0
10 III 25 475   5.0
11 II  5 495  10.0
12 II 10 490  20.0
13 II 25 475  50.0
14 I  5 495 100
15 I 10 490 200
5 Specimen collection and sample preparation
5.1 Specimen collection
The urine samples are collected in suitable urine collection containers and stored at −20 ℃ until analysis.
5.2 Sample preparation
Prior to analysis, the samples are thawed at room temperature and mixed thoroughly. For sample preparation,
0.5 ml of the urine sample are transferred into a 2 ml crimp top vial and 5 µl of the ISTD spiking solution are added.
Afterwards, 1 ml of the ammonium acetate buffer is added. The sample is thoroughly mixed on a laboratory shaker.
For hydrolysis, 5 µl of β-glucuronidase are added to the sample, the vial is sealed and the solution is thoroughly
mixed. The sample is incubated for three hours in the incubator at 37 ℃. After cooling to room temperature, the
sample is directly injected into the UPLC-MS/MS system for analysis.
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6 Operational parameters
Analysis was performed using a UPLC system with two gradient pumps coupled to a tandem mass spectrometer.
6.1 Ultra performance liquid chromatography (UPLC)
Analytical column: Zorbax RRHD Eclipse Plus C8 1.8 μm, 2.1 mm × 100 mm
Pre-concentration column: XBridge BEH C8 Direct Connect HP 10 μm, 2.1 mm × 30 mm
Mobile phase: Mobile phase A: ultrapure water with 0.1% formic acid
Mobile phase B: acetonitrile with 0.1% formic acid
Column temperature: 40 ℃
Injection volume: 25 µl
Column switching program: 0–0.5 min: valve 1 – position 1; valve 2 – position 1
0.5–3.5 min: valve 1 – position 2; valve 2 – position 1
3.5–10 min: valve 1 – position 1; valve 2 – position 1
(cf. Figure 2 in the Appendix)
Gradient program: see Tables 3 and 4
Tab. 3 Program of gradient pump 1
Time Mobile phase A Mobile phase B Flow rate
[min] [Vol.-%] [Vol.-%] [ml/min]
 0.0 90  10 0.8
 1.0 90  10 0.8
 1.5  0 100 0.8
 3.0  0 100 0.8
 3.5 90  10 0.8
10 90  10 0.8
Tab. 4 Program of gradient pump 2
Time Mobile phase A Mobile phase B Flow rate
[min] [Vol.-%] [Vol.-%] [ml/min]
 0.0 90 10 0.3
 1.0 90 10 0.3
 7.0  5 95 0.3
 9.0  5 95 0.3
 9.5 90 10 0.3
10 90 10 0.3
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6.2 Tandem mass spectrometry
Ionisation type: positive electrospray ionisation (ESI+)
Source temperature: 150 ℃
Desolvation temperature: 400 ℃
Cone gas flow: 150 l/h
Desolvation gas flow: 700 l/h
Collision gas flow: 0.15 ml/h
Nebuliser gas flow: 6.0 bar
Parameter-specific settings: see Table 5
Tab. 5 Parameter-specific settings for the analyte and the internal standard
Ion trace [m/z]Analyte Retention time











13C6-BHT acid 6.11 257.3
 57.1 47.0 16.0
a) Qualifier
All settings are instrument-specific and must be adjusted individually by the user. The parameters specified above
are therefore intended as a rough guide only. All other parameters have to be optimised in accordance with the
manufacturer’s specifications.
7 Analytical determination
25 µl each of the samples prepared as described in Section 5 are injected into the UPLC-MS/MS system.The analyte is
enriched on the pre-column and then backflushed to the analytical column for analytical separation. Identification
of the analyte is based on the retention time and the specific ion transitions. The retention times of the analyte
and of the internal standard as well as the recorded ion transitions are listed in Table 5. The qualifier transitions
are only used to confirm the identity of the analyte. Depending on matrix interferences, it may be advisable in
some cases to quantify the analyte using one of the qualifiers instead of the actual quantifier. In such cases, the
calibration graph must be created accordingly.
The retention times given in Table 5 are intended as a rough guide only. Users must ensure proper separation
performance of the UPLC column used influencing the resulting retention behaviour of the analyte. Figures 3
and 4 (in the Appendix) show, as an example, chromatograms of a native urine sample and of a spiked water sample
(calibration standard).
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8 Calibration
The calibration standards described in Section 4.5 are prepared and processed in the same way as the samples (cf.
Section 5.2) and analysed using LC-MS/MS (cf. Section 6). Calibration graphs are obtained by plotting the quotients
of the peak areas of the analyte and of the 13C6-labelled internal standard against the spiked concentration of the
respective calibration standards. A quadratic calibration graph is obtained in the concentration range from the
detection limit to 200 µg/l. Three reagent blanks (ultrapure water instead of the urine sample) and three quality
control samples (see Section 10) are included in each analytical run.
Figure 5 (in the Appendix) shows an example of a calibration graph of the analyte prepared in water. Calibration
is performed in water instead of urine due to the ubiquitous background levels of BHT acid in human urine.
9 Calculation of the analytical results
The determined peak areas of the BHT acid are divided by the peak areas of the 13C6-labelled internal standard.
The quotients thus obtained are entered in the calibration function established according to Section 8 to give the
analyte concentration in µg/l. Any reagent blank values have to be subtracted from the analytical results. The
analyte concentration was calculated using the Waters MassLynx 4.1 software.
10 Standardisation and quality control
Quality control of the analytical results is carried out as stipulated in the guidelines of the Bundesärztekammer
(German Medical Association) and in a general chapter of the MAK Collection for Occupational Health and Safety
(Bader et al. 2010; Bundesärztekammer 2014). To check precision, at least three quality control samples with known
analyte concentrations are analysed within each analytical run. As material for quality control is not commercially
available, it must be prepared in the laboratory. To this end, spiking solutions of the analyte are added to ultrapure
water, so that the concentrations of the control materials are within the relevant concentration range (e.g. 1 µg/l,
10 µg/l and 100 µg/l). For this purpose, the spiking solutions are prepared separately of those used for calibration
(separate weighing procedure). Aliquots of these samples are stored at −20 ℃ and included in each analytical run as
quality control samples.The nominal values and the tolerance ranges of the quality control materials are determined
in a pre-analytical period (one analysis of the control materials each on 10 different days) (Bader et al. 2010).
At the same time, at least three reagent blanks are included in each analytical run to identify potential interferences
caused by the chemicals used (cf. Section 11.5).
11 Evaluation of the method
The reliability of the method was verified by comprehensive validation as well as by implementation and validation
of the method in a second, independent laboratory.
11.1 Precision
Within-day precision was determined in both water and urine. To this end, ultrapure water was spiked with BHT
acid at concentration levels of 0.1 µg/l, 1.0 µg/l, 10 µg/l and 100 μg/l, respectively, and analysed ten times in a row.
In addition, pooled urine was spiked with BHT acid at concentration levels of 1.0 µg/l and 10 µg/l, respectively,
and analysed ten times in a row. The spiked samples were prepared and analysed as described in Section 5.2 and
Section 6. Moreover, an unspiked native urine sample was processed nine times and analysed.
The thus obtained within-day precision data are presented in Table 6.
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Tab. 6 Within-day precision for the determination of BHT acid (n = 9 and n = 10, respectively)
Spiked level Standard deviation (rel.) Prognostic rangeMatrix






  1.0 11.4 25.8Pooled urine
 10.0 11.0 24.9
Unspiked urine sample –a)  6.6 15.2
a) determined mean native concentration: 26.8 µg/l
To determine day-to-day precision, water was spiked and analysed ten times over a period of 2.5 days. The thus
obtained day-to-day precision data are presented in Table 7.
Tab. 7 Day-to-day precision for the determination of BHT acid (n = 10)
Spiked level Standard deviation (rel.) Prognostic rangeMatrix







The accuracy of the method was determined on the basis of the within-day precision data and the day-to-day preci-
sion data. In addition, ten individual urine samples were spiked with 1.0 and 10 µg/l BHT acid each, respectively, to
determine the impact of different urine matrices. The relative recovery rates thus obtained are presented in Tables 8
and 9.
Tab. 8 Relative recovery rates for the determination of BHT acid, derived from the within-day precision data (n = 10) or from the
analysis of spiked individual urine samples (n = 10)
Spiked level Recovery (rel.) RangeMatrix






  1.0  95 80–111Pooled urine
 10.0  87 73–99
  1.0  97 78–119Individual urine samples
 10.0  95 85–105
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Tab. 9 Relative recovery rates for the determination of BHT acid, derived from the day-to-day precision data (n = 10)
Spiked level Recovery (rel.) RangeMatrix







In order to assess the need for hydrolysis, 17 native urine samples from individuals who could have come into
contact with BHT at their workplace were processed and analysed with and without hydrolysis. The level of free
BHT acid (without hydrolysis) and total BHT acid (free plus conjugated BHT acid, with hydrolysis) was determined.
The results obtained are shown in Table 10.
Tab. 10 Determination of BHT acid in urine with or without enzymatic hydrolysis (n = 17)
BHT acid [µg/l]Hydrolysis
Median (mean value) Range
> LOQ [%]
without hydrolysis 0.52 (2.07) < 0.2–12.1  82.4
enzymatic hydrolysis (β-glucuronidase) 4.11 (8.44) 0.9–32.5 100
In order to compare enzymatic hydrolysis with acidic hydrolysis, urine samples of 22 individuals who were occu-
pationally exposed to BHT were analysed. The results are presented in Table 11.
Tab. 11 Determination of BHT acid in urine using enzymatic or acidic hydrolysis (n = 22)
BHT acid [µg/l]Hydrolysis
Median (mean value) Range
> LOQ [%]
enzymatic hydrolysis (β-glucuronidase) 4.55 (6.47) 0.7–26.6 100
acidic hydrolysis (hydrochloric acid) 3.84 (6.05) 0.5–26.7 100
Moreover, five of the high-exposure samples from this group were selected and compared regarding their results
following hydrolysis with acid or with two different enzymes (glucuronidase or glucuronidase/arylsulfatase). The
results are presented in Table 12.
Tab. 12 Determination of BHT acid in urine using two different enzymes or acidic hydrolysis (n = 5)
BHT acid [µg/l]Hydrolysis
Sample 1 Sample 2 Sample 3 Sample 4 Sample 5
enzymatic hydrolysis
(β-glucuronidase/arylsulfatase H. pomatia)
26.6 n. s. 10.5 24.3 11.4
enzymatic hydrolysis
(β-glucuronidase E. coli)
24.4 5.03 10.7 20.3 13.1
acidic hydrolysis (hydrochloric acid) 19.6 4.48  9.06 26.7 14.4
n. s. = not specified (due to matrix interferences of the internal standard)
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In order to determine the reproducibility of the enzymatic hydrolysis, a native urine sample was processed ten
times and then analysed. The obtained data from nine measurements are shown in Table 13.










11.4 Limit of detection and limit of quantitation
The detection limit and quantitation limit were determined according to DIN 32645 (DIN 2008) using the six lowest
points of a calibration curve prepared in water. The limit of detection and quantitation calculated on the basis of
the method standard deviation sx0 (LOD = 4 × sx0) are shown in Table 14.
Tab. 14 Limit of detection and quantitation for the determination of BHT acid




BHT acid Water 0.06 0.2
11.5 Sources of error
The objective of the method development was to reach a detection limit of at least 0.1 µg/l. This proved to be
very ambitious as a distinct background level of BHT acid was observed in all urine samples analysed. Due to
this background level, calibration in urine was not feasible. Therefore, the calibration standards were prepared
in water, thus resolving the problem of background levels. Despite calibration in water, a constant blank value
of approximately 0.3 µg/l was still detected. The ammonium acetate used, which contained traces of BHT acid
despite its p.a. specification, was identified as the main source of this blank value. The blank could be reduced to
approximately 0.12 µg/l by using ultrapure ammonium acetate for mass spectrometry. The deionised water (Milli‑Q
water) initially used was also considered as a possible source of BHT acid, as microbial degradation of BHT from
the filter material could not be ruled out. The water was thus replaced by ultrapure LC-MS grade water and, at the
same time, a trap column was installed upstream of the analytical column for each LC pump, respectively. These
measures helped to reduce the blank to approximately 0.05 µg/l.
During method development, the need of hydrolysis in order to release the BHT acid from its conjugates was con-
firmed (see Section 11.3). Subsequently, various hydrolysis options were tested. It was observed that no significant
difference in the release of BHT acid could be detected when using glucuronidase and glucuronidase/arylsulfatase
compared to acidic hydrolysis. However, outliers were repeatedly detected in spiked urine samples following acidic
hydrolysis (probably caused by quenching). And, after enzymatic hydrolysis with glucuronidase/arylsulfatase, el-
evated background levels of BHT acid were found, which was not the case after hydrolysis using glucuronidase
only. For this reason, glucuronidase was chosen for hydrolysis. In this way, the blank-related background levels
could be further reduced to approximately 0.02 µg/l. All in all, the described measures enabled a detection limit of
0.06 µg/l and a quantitation limit of 0.2 µg/l.
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12 Discussion of the method
The described analytical method permits the selective and sensitive determination of BHT acid in urine. The rapid
and robust analysis allows for the screening of large sample numbers.
By use of the column-switching LC-MS/MS technique, the entire analysis and sample processing (hydrolysis, clean
up and quantification) can be performed using only one sample vial, thus minimising process-related analyte losses.
The analyte enrichment and the clean-up of the hydrolysed samples is performed on a Waters XBridge C8 column,
the analytical separation on a Zorbax RRHD Eclipse Plus C8 column.
Compared to the acidic hydrolysis described in the literature, the enzymatic hydrolysis used in the present method
leads to chromatograms with considerably lower noise. The comparative analysis of 22 urine samples from poten-
tially exposed individuals confirmed the suitability of the used enzymatic hydrolysis instead of acidic hydrolysis.
The use of the structurally identical 13C6-labelled internal standard renders it possible to compensate for almost all
analytical fluctuations, which is confirmed by the good precision data.
In the course of external method verification, calibrationwas performed using linear regression, with the calibration
curve forced through the origin. The working range was also up to 200 µg/l and comparable validation data were
obtained.
Instruments used Waters Acquity UPLC coupled with Waters Xevo-TQS tandem mass spectrometer (Waters
GmbH, Eschborn, Germany).
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Appendix
Fig. 2 Schematic representation of the column switching program
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Fig. 3 Chromatogram of a native urine sample with a determined level of BHT acid of approximately 10 µg/l
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Fig. 4 Chromatogram of a calibration standard in water with a spiked level of BHT acid of 10 µg/l
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Fig. 5 Calibration curve of BHT acid in water
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